



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

INTER-EWING-1

The University of Birmingham in the United Kingdom (sponsor) is responsible for the international conduct of the study. In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is the national sponsor representative responsible for the study.

Background

Ewing sarcoma is a malignant tumour that usually affects the bones. Ewing sarcomas account for around 2% of all cancers in childhood and adolescence. Most patients are adolescents or young adults.

Treatment methods have improved in recent years. Nevertheless, in 30–40% of patients with Ewing sarcoma, the disease returns after initial treatment (relapse).

In Switzerland, around 10–15 patients could take part in this clinical study each year.

Why is the study necessary?

The aim of the INTER-EWING-1 clinical study is to reduce the number of relapses in patients with Ewing sarcoma and increase survival rates. The research questions are whether an additional course of chemotherapy at the end of standard chemotherapy and whether an adjusted radiation dose improve treatment outcomes.

The researchers also want to find out how the different therapies affect quality of life. For this purpose, patients and/or their parents are given questionnaires.

The findings from the study are intended to improve therapy. The goal: fewer relapses and higher survival rates while maintaining the best possible quality of life.

Contact details for the Swiss sponsor representative:

SPOG Coordinating Centre

Partner Relations

3008 Bern

E-mail: partnerrelations@spog.ch

Tel.: +41 31 389 91 89